Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

MLA

Igle J. de Jong, et al. “Clinical Activity and Tolerability of Enzalutamide (MDV3100) in Patients with Metastatic, Castration-Resistant Prostate Cancer Who Progress after Docetaxel and Abiraterone Treatment.” Cancer, vol. 120, Dec. 2013, pp. 968–75. EBSCOhost, https://doi.org/10.1002/cncr.28518.

APA

Igle J. de Jong, Emile D. Kerver, Andries M. Bergman, Sushil K Badrising, H. Pieter van den Berg, Paul Hamberg, Harm van Tinteren, Jules L.L.M. Coenen, Inge M. van Oort, Alfons J.M. van den Eertwegh, Vincent van der Noort, & Maartje Los. (2013). Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer, 120, 968–975. https://doi.org/10.1002/cncr.28518

Chicago

Igle J. de Jong, Emile D. Kerver, Andries M. Bergman, Sushil K Badrising, H. Pieter van den Berg, Paul Hamberg, Harm van Tinteren, et al. 2013. “Clinical Activity and Tolerability of Enzalutamide (MDV3100) in Patients with Metastatic, Castration-Resistant Prostate Cancer Who Progress after Docetaxel and Abiraterone Treatment.” Cancer 120 (December): 968–75. doi:10.1002/cncr.28518.